Functional biomarkers of depression: Diagnosis, treatment, and pathophysiology

Neuropsychopharmacology

Volumn 36, Issue 12, 2011, Pages 2375-2394

  Schmidt, Heath D ^a   Shelton, Richard C ^b   Duman, Ronald S ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antidepressant; BDNF; IGF 1; IL 1 ; mood disorders; serum

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CELECOXIB; CYTOKINE; ETANERCEPT; GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 6; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

BEHAVIOR; BRAIN FUNCTION; COGNITIVE THERAPY; DISEASE MARKER; ENDOCRINE SYSTEM; HEREDITY; HUMAN; MAJOR DEPRESSION; METABOLIC REGULATION; MOOD DISORDER; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM FUNCTION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; STRESS; SYNAPSE; TREATMENT RESPONSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; BRAIN; CYTOKINES; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; TREATMENT OUTCOME;

EID: 80054756091     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.151     Document Type: Review

References (247)

1. Aberg MA, Aberg ND, Hedbacker H, Oscarsson J, Eriksson PS (2000). Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci 20: 2896-2903. (Pubitemid 30220315)
2. Adriaanse MC, Dekker JM, Nijpels G, Heine RJ, Snoek FJ, Pouwer F (2006). Associations between depressive symptoms and insulin resistance: The Hoorn Study. Diabetologia 49: 2874-2877. (Pubitemid 44730290)
3. Akbaraly TN, Ancelin ML, Jaussent I, Ritchie C, Barberger-Gateau P, Dufouil C et al (2011). Metabolic syndrome and onset of depressive symptoms in the elderly: Findings from the three-city study. Diabetes Care 34: 904-909.
4. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, Latoussakis V, Kanellopoulos D, Klimstra S et al (2008). Microstructural white matter abnormalities and remission of geriatric depression. Am J Psychiatry 165: 238-244. (Pubitemid 351704524)
5. Altar CA, Laeng P, Jurata LW, Brockman JA, Lemire A, Bullard J et al (2004). Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 24: 2667-2677. (Pubitemid 38380943)
6. Altman DG, Bland JM (1994). Diagnostic tests 2: Predictive values. BMJ 309: 102. (Pubitemid 24216428)
7. Ancelin ML, Carriere I, Boulenger JP, Malafosse A, Stewart R, Cristol JP et al (2010). Gender and genotype modulation of the association between lipid levels and depressive symptomatology in community-dwelling elderly (the ESPRIT study). Biol Psychiatry 68: 125-132.
8. Anderson MF, Aberg MA, Nilsson M, Eriksson PS (2002). Insulinlike growth factor-I and neurogenesis in the adult mammalian brain. Brain Res Dev Brain Res 134: 115-122. (Pubitemid 34310242)
9. Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR et al (2009). Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360: 1310-1319.
10. Anlar B, Sullivan KA, Feldman EL (1999). Insulin-like growth factor-I and central nervous system development. Horm Metab Res 31: 120-125. (Pubitemid 29169485)
11. Aydemir C, Yalcin ES, Aksaray S, Kisa C, Yildirim SG, Uzbay T et al (2006). Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog Neuropsychopharmacol Biol Psychiatry 30: 1256-1260. (Pubitemid 44216065)
12. Aydemir O, Deveci A, Taneli F (2005). The effect of chronic antidepressant treatment on serum brain-derived neurotrophicfactor levels in depressed patients: A preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 29: 261-265. (Pubitemid 40202912)
13. Balk SP, Ko YJ, Bubley GJ (2003). Biology of prostate-specific antigen. J Clin Oncol 21: 383-391. (Pubitemid 46606169)
14. Banks WA (2005). Blood-brain barrier transport of cytokines: A mechanism for neuropathology. Curr Pharm Des 11: 973-984. (Pubitemid 40331299)
15. Baron RM, Kenny DA (1986). The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51: 1173-1182.
16. Barrientos RM, Sprunger DB, Campeau S, Higgins EA, Watkins LR, Rudy JW et al (2003). Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neuroscience 121: 847-853. (Pubitemid 37324583)
17. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ et al (2006). Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311: 864-868. (Pubitemid 43228853)
18. Besedovsky HO, del Rey A (1996). Immune-neuro-endocrine interactions: Facts and hypotheses. Endocr Rev 17: 64-102. (Pubitemid 26061368)
19. Bezchlibnyk YB, Xu L, Wang JF, Young LT (2007). Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Res 1147: 213-217. (Pubitemid 46574546)
20. Bocchio-Chiavetto L, Zanardini R, Bortolomasi M, Abate M, Segala M, Giacopuzzi M et al (2006). Electroconvulsive therapy (ECT) increases serum brain derived neurotrophic factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol 16: 620-624. (Pubitemid 44781079)
21. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M (2002). Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72: 237-241. (Pubitemid 35351283)
22. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M et al (2001). Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 105: 45-55. (Pubitemid 34015882)
23. Bondy CA, Lee WH (1993). Patterns of insulin-like growth factor and IGF receptor gene expression in the brain. Functional implications. Ann NY Acad Sci 692: 33-43. (Pubitemid 23299514)
24. Braun A, Lommatzsch M, Mannsfeldt A, Neuhaus-Steinmetz U, Fischer A, Schnoy N et al (1999). Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol 21: 537-546. (Pubitemid 129504276)
25. Brunoni AR, Lopes M, Fregni F (2008a). A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11: 1169-1180.
26. Brunoni AR, Lopes M, Fregni F (2008b). A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11: 1169-1180.
27. Bush DE, Sotres-Bayon F, LeDoux JE (2007). Individual differences in fear: Isolating fear reactivity and fear recovery phenotypes. J Trauma Stress 20: 413-422. (Pubitemid 47475492)
28. Cao JL, Covington III HE, Friedman AK, Wilkinson MB, Walsh JJ, Cooper DC et al (2010). Mesolimbic dopamine neurons in the brain reward circuit mediate susceptibility to social defeat and antidepressant action. J Neurosci 30: 16453-16458.
29. Capuron L, Dantzer R (2003). Cytokines and depression: The need for a new paradigm. Brain Behav Immun 17(Suppl 1): S119-S124. (Pubitemid 36298524)
30. Capuron L, Ravaud A, Dantzer R (2001a). Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med 63: 376-386. (Pubitemid 32467112)
31. Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M et al (2001b). Association between immune activation and early depressive symptoms in cancer patients treated with interleukin- 2-based therapy. Psychoneuroendocrinology 26: 797-808. (Pubitemid 32918284)
32. Carro E, Nunez A, Busiguina S, Torres-Aleman I (2000). Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci 20: 2926-2933. (Pubitemid 30220318)
33. Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I (2005). Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 25: 10884-10893. (Pubitemid 41692618)
34. Cassilhas RC, Antunes HK, Tufik S, de Mello MT (2010). Mood, anxiety, and serum IGF-1 in elderly men given 24 weeks of high resistance exercise. Percept Mot Skills 110: 265-276.
35. Castren E, Rantamaki T (2010). The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol 70: 289-297.
36. Cattaneo A, Sesta A, Calabrese F, Nielsen G, Riva MA, Gennarelli M (2010). The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology 35: 1423-1428.
37. Chen AC, Eisch AJ, Sakai N, Takahashi M, Nestler EJ, Duman RS (2001a). Regulation of GFRalpha-1 and GFRalpha-2 mRNAs in rat brain by electroconvulsive seizure. Synapse 39: 42-50.
38. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001b). Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 50: 260-265. (Pubitemid 32778442)
39. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ et al (2006). Genetic variant BDNF (Val66Met) polymorphism alters anxietyrelated behavior. Science 314: 140-143. (Pubitemid 44547760)
40. Cryan JF, Page ME, Lucki I (2005). Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl) 182: 335-344. (Pubitemid 41464645)
41. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008). From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 9: 46-56. (Pubitemid 350295688)
42. De Berardis D, Campanella D, Gambi F, La Rovere R, Carano A, Conti CM et al (2006). The role of C-reactive protein in mood disorders. Int J Immunopathol Pharmacol 19: 721-725. (Pubitemid 46145036)
43. D'Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G (1996). The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol 13: 227-255. (Pubitemid 126715878)
44. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM et al (2005). Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 62: 409-416. (Pubitemid 40471690)
45. Dieperink E, Willenbring M, Ho SB (2000). Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 157: 867-876. (Pubitemid 30412335)
46. Dinan TG (2009). Inflammatory markers in depression. Curr Opin Psychiatry 22: 32-36.
47. Diniz BS, Teixeira AL, Talib L, Gattaz WF, Forlenza OV (2010). Interleukin-1beta serum levels is increased in antidepressantfree elderly depressed patients. Am J Geriatr Psychiatry 18: 172-176.
48. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A et al (2010). Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 5: E9166.
49. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al (2010). A meta-analysis of cytokines in major depression. Biol Psychiatry 67: 446-457.
50. Duman CH, Schlesinger L, Kodama M, Russell DS, Duman RS (2007). A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 61: 661-670. (Pubitemid 46328865)
51. Duman CH, Schlesinger L, Russell DS, Duman RS (2008a). Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. Brain Res 1199: 148-158.
52. Duman CH, Schlesinger L, Terwilliger R, Russell DS, Newton SS, Duman RS (2008b). Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res 198: 366-371.
53. Duman CH, Schlesinger L, Terwilliger R, Russell DS, Newton SS, Duman RS (2009). Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res 198: 366-371.
54. Dunbar JA, Reddy P, Davis-Lameloise N, Philpot B, Laatikainen T, Kilkkinen A et al (2008). Depression: An important comorbidity with metabolic syndrome in a general population. Diabetes Care 31: 2368-2373.
55. Dunger DB, Ong KK, Sandhu MS (2003). Serum insulin-like growth factor-I levels and potential risk of type 2 diabetes. Horm Res 60(Suppl 3): 131-135. (Pubitemid 37548216)
56. Dunn AJ, Swiergiel AH, de Beaurepaire R (2005). Cytokines as mediators of depression: What can we learn from animal studies? Neurosci Biobehav Rev 29: 891-909. (Pubitemid 40755469)
57. Dunn BK, Jegalian K, Greenwald P (2011). Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: Issues and opportunities. Recent Results Cancer Res 188: 21-47.
58. Dwivedi Y, Mondal AC, Rizavi HS, Conley RR (2005). Suicide brain is associated with decreased expression of neurotrophins. Biol Psychiatry 58: 315-324. (Pubitemid 41133625)
59. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2003). Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60: 804-815. (Pubitemid 36960912)
60. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257-269. (Pubitemid 36144114)
61. Eisch AJ, Bolanos CA, de Wit J, Simonak RD, Pudiak CM, Barrot M et al (2003). Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: A role in depression. Biol Psychiatry 54: 994-1005. (Pubitemid 37415034)
62. Ejiri J, Inoue N, Kobayashi S, Shiraki R, Otsui K, Honjo T et al (2005). Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. Circulation 112: 2114-2120. (Pubitemid 41475804)
63. Elfving B, Plougmann PH, Wegener G (2010). Differential brain, but not serum VEGF levels in a genetic rat model of depression. Neurosci Lett 474: 13-16.
64. Eller T, Vasar V, Shlik J, Maron E (2008). Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32: 445-450. (Pubitemid 351178962)
65. Elliott E, Ezra-Nevo G, Regev L, Neufeld-Cohen A, Chen A (2010). Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice. Nat Neurosci 13: 1351-1353.
66. Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, Tomita H et al (2004). Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 101: 15506-15511. (Pubitemid 39441571)
67. Fabel K, Fabel K, Tam B, Kaufer D, Baiker A, Simmons N et al (2003). VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci 18: 2803-2812. (Pubitemid 37542133)
68. Feder A, Nestler EJ, Charney DS (2009). Psychobiology and molecular genetics of resilience. Nat Rev Neurosci 10: 446-457.
69. Fertuzinhos SM, Oliveira JR, Nishimura AL, Pontual D, Carvalho DR, Sougey EB et al (2004). Analysis of IL-1alpha, IL-1beta, and IL-1RA [correction of IL-RA] polymorphisms in dysthymia. J Mol Neurosci 22: 251-256.
70. Fink M, Taylor MA (2007). Resurrecting melancholia. Acta Psychiatr Scand Suppl 433: 14-20. (Pubitemid 46114835)
71. Fournier JC, DeRubeis RJ, Shelton RC, Hollon SD, Amsterdam JD, Gallop R (2009). Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol 77: 775-787.
72. Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR et al (2009). Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 14: 681-695.
73. Gaughran F, Payne J, Sedgwick PM, Cotter D, Berry M (2006). Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res Bull 70: 221-227. (Pubitemid 44067346)
74. Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G et al (2005). Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 51: 234-238. (Pubitemid 40976406)
75. Gold PW, Chrousos GP (2002). Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol Psychiatry 7: 254-275. (Pubitemid 34280634)
76. Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S (2005). Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 255: 381-386. (Pubitemid 43029827)
77. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T et al (2008). Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 13: 717-728. (Pubitemid 351861529)
78. Goshen I, Yirmiya R (2009). Interleukin-1 (IL-1): A central regulator of stress responses. Front Neuroendocrinol 30: 30-45.
79. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ (2010). Brain-derived neurotrophic factor levels in schizophrenia: A systematic review with meta-analysis. Mol Psychiatry. (e-pub ahead of print
80. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS (2009). Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: Pharmacological and cellular characterization. Neuropsychopharmacology 34: 2459-2468.
81. Han JC, Muehlbauer MJ, Cui HN, Newgard CB, Haqq AM (2010). Lower brain-derived neurotrophic factor in patients with Prader-Willi syndrome compared to obese and lean control subjects. J Clin Endocrinol Metab 95: 3532-3536.
82. Heine VM, Zareno J, Maslam S, Joels M, Lucassen PJ (2005). Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur J Neurosci 21: 1304-1314. (Pubitemid 40516629)
83. Hendrickx H, McEwen BS, Ouderaa F (2005). Metabolism, mood and cognition in aging: The importance of lifestyle and dietary intervention. Neurobiol Aging 26(Suppl 1): 1-5.
84. Himmerich H, Milenovic S, Fulda S, Plumakers B, Sheldrick AJ, Michel TM et al (2010). Regulatory T cells increased while IL- 1beta decreased during antidepressant therapy. J Psychiatr Res 44: 1052-1057.
85. Hock C, Heese K, Muller-Spahn F, Huber P, Riesen W, Nitsch RM et al (2000). Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression. Mol Psychiatry 5: 510-513.
86. Hoshaw BA, Malberg JE, Lucki I (2005). Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 1037: 204-208. (Pubitemid 40362398)
87. Howren MB, Lamkin DM, Suls J (2009a). Associations of depression with C-reactive protein, IL-1, and IL-6: A metaanalysis. Psychosom Med 71: 171-186.
88. Howren MB, Lamkin DM, Suls J (2009b). Associations of depression with C-reactive protein, IL-1, and IL-6: A metaanalysis. Psychosom Med 71: 171-186.
89. Huang TL, Lee CT, Liu YL (2008). Serum brain-derived neurotrophic factor levels in patients with major depression: Effects of antidepressants. J Psychiatr Res 42: 521-525.
90. Hunsberger JG, Newton SS, Bennett AH, Duman CH, Russell DS, Salton SR et al (2007). Antidepressant actions of the exerciseregulated gene VGF. Nat Med 13: 1476-1482. (Pubitemid 350224242)
91. Iga JI, Ueno SI, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S et al (2006). Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31: 658-663.
92. Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z et al (2006). Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 26: 9703-9712. (Pubitemid 44427709)
93. Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Perlis RH, Papakostas GI et al (2006). Brain white-matter hyperintensities and treatment outcome in major depressive disorder. Br J Psychiatry 188: 180-185. (Pubitemid 43171076)
94. Jazayeri S, Keshavarz SA, Tehrani-Doost M, Djalali M, Hosseini M, Amini H et al (2010). Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res 178: 112-115.
95. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA (2002). Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 99: 11946-11950. (Pubitemid 34994504)
96. Johnson JD, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN et al (2005). Catecholamines mediate stressinduced increases in peripheral and central inflammatory cytokines. Neuroscience 135: 1295-1307. (Pubitemid 41416690)
97. Kahl KG, Bens S, Ziegler K, Rudolf S, Dibbelt L, Kordon A et al (2006). Cortisol, the cortisol-dehydroepiandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. Biol Psychiatry 59: 667-671. (Pubitemid 43357963)
98. Kahl KG, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L et al (2009). Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 34: 353-357.
99. Kaldunski M, Jia S, Geoffrey R, Basken J, Prosser S, Kansra S et al (2010). Identification of a serum-induced transcriptional signature associated with type 1 diabetes in the BioBreeding rat. Diabetes 59: 2375-2385.
100. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL (2005). Insulin-like growth factors and coronary heart disease. Cardiol Rev 13: 35-39. (Pubitemid 40204695)
101. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM (2002). Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109: 143-148. (Pubitemid 34258493)
102. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R (2005). Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 136: 29-37. (Pubitemid 40704606)
103. Katon WJ (2008). The comorbidity of diabetes mellitus and depression. Am J Med 121(11 Suppl 2): S8-15.
104. Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV (2001). Reduced serum insulin-like growth factor- 1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res 11: 364-367. (Pubitemid 34428879)
105. Kenis G, Prickaerts J, van Os J, Koek GH, Robaeys G, Steinbusch HW et al (2010). Depressive symptoms following interferonalpha therapy: Mediated by immune-induced reductions in brain-derived neurotrophic factor? Int J Neuropsychopharmacol 14: 247-253.
106. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSMIV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617-627. (Pubitemid 40973437)
107. Khairova RA, Machado-Vieira R, Du J, Manji HK (2009). A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 12: 561-578.
108. Khawaja X, Xu J, Liang JJ, Barrett JE (2004). Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: Implications for depressive disorders and future therapies. J Neurosci Res 75: 451-460. (Pubitemid 38160706)
109. Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH et al (2007a). Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry 31: 78-85.
110. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB (2007b). Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31: 1044-1053.
111. Kobayashi K, Shimizu E, Hashimoto K, Mitsumori M, Koike K, Okamura N et al (2005). Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: As a biological predictor of response to group cognitive behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry 29: 658-663. (Pubitemid 40897773)
112. Koliatsos VE, Clatterbuck RE, Winslow JW, Cayouette MH, Price DL (1993). Evidence that brain-derived neurotrophic factor is a trophic factor for motor neurons in vivo. Neuron 10: 359-367. (Pubitemid 23111729)
113. Koo JW, Duman RS (2008). IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 105: 751-756. (Pubitemid 351171780)
114. Kraemer HC, Schultz SK, Arndt S (2002a). Biomarkers in psychiatry: Methodological issues. Am J Geriatr Psychiatry 10: 653-659. (Pubitemid 35315701)
115. Kraemer HC, Wilson GT, Fairburn CG, Agras WS (2002b). Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 59: 877-883.
116. Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M et al (2007a). Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 157: 1275-1277. (Pubitemid 350115684)
117. Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ et al (2007b). Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131: 391-404. (Pubitemid 47576141)
118. Krishnan V, Nestler EJ (2008). The molecular neurobiology of depression. Nature 455: 894-902.
119. Laje G, Perlis RH, Rush AJ, McMahon FJ (2009). Pharmacogenetics studies in STAR*D: Strengths, limitations, and results. Psychiatr Serv 60: 1446-1457.
120. Lakhan SE, Vieira K, Hamlat E (2010). Biomarkers in psychiatry: Drawbacks and potential for misuse. Int Arch Med 3: 1.
121. Lawlor DA, Smith GD, Ebrahim S (2003). Association of insulin resistance with depression: Cross sectional findings from the British Women's Heart and Health Study. BMJ 327: 1383-1384. (Pubitemid 37543947)
122. Lee BH, Kim H, Park SH, Kim YK (2006). Decreased plasma BDNF level in depressive patients. J Affect Disord 101: 239-244.
123. Lee JH, Wang LC, Yu HH, Lin YT, Yang YH, Chiang BL (2010). Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma. Mediators Inflamm 2010: 567351.
124. Lee JS, Jang DJ, Lee N, Ko HG, Kim H, Kim YS et al (2009). Induction of neuronal vascular endothelial growth factor expression by cAMP in the dentate gyrus of the hippocampus is required for antidepressant-like behaviors. J Neurosci 29: 8493-8505.
125. Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ et al (2009). Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 14: 156-174.
126. Leuchter AF, Cook IA, Hamilton SP, Narr KL, Toga A, Hunter AM et al (2010). Biomarkers to predict antidepressant response. Curr Psychiatry Rep 12: 553-562.
127. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309. (Pubitemid 20066716)
128. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V (1999). Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40: 171-176. (Pubitemid 29515729)
129. Lin E, Chen PS (2008). Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 9: 935-946.
130. Linthorst AC, Flachskamm C, Holsboer F, Reul JM (1994). Local administration of recombinant human interleukin-1 beta in the rat hippocampus increases serotonergic neurotransmission, hypothalamic-pituitary-adrenocortical axis activity, and body temperature. Endocrinology 135: 520-532.
131. Liu J, Garza JC, Bronner J, Kim CS, Zhang W, Lu XY (2010). Acute administration of leptin produces anxiolytic-like effects: A comparison with fluoxetine. Psychopharmacology 207: 535-545.
132. Lohoff FW (2010). Overview of the genetics of major depressive disorder. Curr Psychiatry Rep 12: 539-546.
133. Lommatzsch M, Braun A, Mannsfeldt A, Botchkarev VA, Botchkareva NV, Paus R et al (1999). Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic functions. Am J Pathol 155: 1183-1193. (Pubitemid 29488926)
134. Lommatzsch M, Schloetcke K, Klotz J, Schuhbaeck K, Zingler D, Zingler C et al (2005a). Brain-derived neurotrophic factor in platelets and airflow limitation in asthma. Am J Respir Crit Care Med 171: 115-120. (Pubitemid 40105409)
135. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P et al (2005b). The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 26: 115-123. (Pubitemid 39600596)
136. Lu B, Pang PT, Woo NH (2005). The yin and yang of neurotrophin action. Nat Rev Neurosci 6: 603-614. (Pubitemid 41059335)
137. Lu XY (2007). The leptin hypothesis of depression: A potential link between mood disorders and obesity? Curr Opin Pharmacol 7: 648-652.
138. Lu XY, Kim CS, Frazer A, Zhang W (2006). Leptin: A potential novel antidepressant. Proc Natl Acad Sci USA 103: 1593-1598. (Pubitemid 43191210)
139. Lutter M, Nestler EJ (2009). Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr 139: 629-632.
140. Lutter M, Sakata I, Osborne-Lawrence S, Rovinsky SA, Anderson JG, Jung S et al (2008). The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci 11: 752-753. (Pubitemid 351896679)
141. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H (1997). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9: 853-858. (Pubitemid 27494150)
142. Maier SF, Watkins LR (1995). Intracerebroventricular interleukin- 1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res 695: 279-282.
143. Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE et al (2007). Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 32: 2360-2368. (Pubitemid 47587671)
144. Malinowski DP (2007a). Multiple biomarkers in molecular oncology. I. Molecular diagnostics applications in cervical cancer detection. Expert Rev Mol Diagn 7: 117-131. (Pubitemid 46513440)
145. Malinowski DP (2007b). Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management. Expert Rev Mol Diagn 7: 269-280. (Pubitemid 46798617)
146. Mallei A, Shi B, Mocchetti I (2002). Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal
147. Marrero JA, Kudo M, Bronowicki JP (2010). The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist 15(Suppl 4): 23-33.
148. McIntyre RS, Park KY, Law CW, Sultan F, Adams A, Lourenco MT et al (2010). The association between conventional antidepressants and the metabolic syndrome: A review of the evidence and clinical implications. CNS Drugs 24: 741-753.
149. Miller AH, Maletic V, Raison CL (2009). Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65: 732-741.
150. Molteni R, Fumagalli F, Magnaghi V, Roceri M, Gennarelli M, Racagni G et al (2001). Modulation of fibroblast growth factor-2 by stress and corticosteroids: From developmental events to adult brain plasticity. Brain Res Brain Res Rev 37: 249-258. (Pubitemid 34020735)
151. Monje ML, Toda H, Palmer TD (2003). Inflammatory blockade restores adult hippocampal neurogenesis. Science 302: 1760-1765. (Pubitemid 37505739)
152. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T et al (2004). Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 101: 10827-10832. (Pubitemid 38955827)
153. Mossner R, Mikova O, Koutsilieri E, Saoud M, Ehlis AC, Muller N et al (2007). Consensus paper of the WFSBP Task Force on Biological Markers: Biological markers in depression. World J Biol Psychiatry 8: 141-174. (Pubitemid 47163382)
154. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B et al (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11: 680-684. (Pubitemid 43989814)
155. Murray CA, Lynch MA (1998). Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J Neurosci 18: 2974-2981. (Pubitemid 28163227)
156. Nakazato M, Hashimoto K, Shimizu E, Kumakiri C, Koizumi H, Okamura N et al (2003). Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. Biol Psychiatry 54: 485-490. (Pubitemid 37289455)
157. Nassenstein C, Braun A, Erpenbeck VJ, Lommatzsch M, Schmidt S, Krug N et al (2003). The neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin- 4 are survival and activation factors for eosinophils in patients with allergic bronchial asthma. J Exp Med 198: 455-467. (Pubitemid 36976056)
158. Nemeroff CB, Musselman DL, Evans DL (1998). Depression and cardiac disease. Depression Anxiety 8(Suppl 1): 71-79. (Pubitemid 28524849)
159. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002). Neurobiology of depression. Neuron 34: 13-25. (Pubitemid 34270695)
160. Newton SS, Collier EF, Hunsberger J, Adams D, Terwilliger R, Selvanayagam E et al (2003). Gene profile of electroconvulsive seizures: Induction of neurotrophic and angiogenic factors. J Neurosci 23: 10841-10851. (Pubitemid 37499691)
161. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR et al (1998). Exposure to acute stress induces brain interleukin- 1beta protein in the rat. J Neurosci 18: 2239-2246. (Pubitemid 28141428)
162. Nibuya M, Morinobu S, Duman RS (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15: 7539-7547.
163. Nibuya M, Takahashi M, Russell DS, Duman RS (1999). Repeated stress increases catalytic TrkB mRNA in rat hippocampus. Neurosci Lett 267: 81-84. (Pubitemid 29251591)
164. O'Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, Kelley KW (2008). Regulation of IGF-I function by proinflammatory cytokines: At the interface of immunology and endocrinology. Cell Immunol 252: 91-110.
165. Okamoto T, Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene- Nakano W, Inoue Y et al (2008). Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillicacid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry 32: 1185-1190.
166. Pace TW, Hu F, Miller AH (2007). Cytokine-effects on glucocorticoid receptor function: Relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 21: 9-19. (Pubitemid 44872932)
167. Pan A, Ye X, Franco OH, Li H, Yu Z, Zou S et al (2008). Insulin resistance and depressive symptoms in middle-aged and elderly Chinese: Findings from the Nutrition and Health of Aging Population in China Study. J Affect Disord 109: 75-82.
168. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998). Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37: 1553-1561. (Pubitemid 28550429)
169. Pan W, Kastin AJ (2000). Interactions of IGF-1 with the bloodbrain barrier in vivo and in situ. Neuroendocrinology 72: 171-178.
170. Papakostas GI, Fava M (2008). Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci 10: 439-451.
171. Papakostas GI, Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Alpert JE et al (2005). Brain MRI white matter hyperintensities and onecarbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiatry Res 140: 301-307. (Pubitemid 41660974)
172. Pardridge WM (2002). Neurotrophins, neuroprotection and the blood-brain barrier. Curr Opin Investig Drugs 3: 1753-1757. (Pubitemid 36266722)
173. Pariante CM (2009). Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann NY Acad Sci 1179: 144-152.
174. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404. (Pubitemid 32234301)
175. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M et al (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511. (Pubitemid 36158056)
176. Perlis RH (2011). Betting on biomarkers. Am J Psychiatry 168: 234-236.
177. Pittenger C, Duman RS (2007). Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology 33: 88-109.
178. Poduslo JF, Curran GL (1996). Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 36: 280-286. (Pubitemid 26095587)
179. Pulford BE, Ishii DN (2001). Uptake of circulating insulin-like growth factors (IGFs) into cerebrospinal fluid appears to be independent of the IGF receptors as well as IGF-binding proteins. Endocrinology 142: 213-220. (Pubitemid 32183683)
180. Qiuhua S, Bergquist-Beringer S, Sousa VD (2011). Major depressive disorder and insulin resistance in nondiabetic young adults in the United States: The National Health and Nutrition Examination Survey, 1999-2002. Biol Res Nurs 13: 175-181.
181. Quilty LC, Meusel LA, Bagby RM (2008). Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder. J Affect Disord 111: 67-73.
182. Raison CL, Capuron L, Miller AH (2006). Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 27: 24-31. (Pubitemid 43083561)
183. Raison CL, Miller AH (2003). When not enough is too much: The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 160: 1554-1565. (Pubitemid 41079539)
184. Rasmusson AM, Shi L, Duman R (2002). Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock. Neuropsychopharmacology 27: 133-142. (Pubitemid 34686965)
185. Reinhardt RR, Bondy CA (1994). Insulin-like growth factors cross the blood-brain barrier. Endocrinology 135: 1753-1761. (Pubitemid 24363863)
186. Rhen T, Cidlowski JA (2005). Antiinflammatory action of glucocorticoidsFnew mechanisms for old drugs. N Engl J Med 353: 1711-1723.
187. Rivier C (1993). Effect of peripheral and central cytokines on the hypothalamic-pituitary-adrenal axis of the rat. Ann NY Acad Sci 697: 97-105. (Pubitemid 24028958)
188. Rosa AR, Frey BN, Andreazza AC, Cereser KM, Cunha AB, Quevedo J et al (2006). Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci Lett 407: 146-150. (Pubitemid 44404148)
189. Russo-Neustadt A, Beard RC, Cotman CW (1999). Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 21: 679-682. (Pubitemid 29486636)
190. Russo-Neustadt A, Ha T, Ramirez R, Kesslak JP (2001). Physical activity-antidepressant treatment combination: Impact on brain-derived neurotrophic factor and behavior in an animal model. Behav Brain Res 120: 87-95. (Pubitemid 32118151)
191. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E et al (2003). Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 23: 349-357. (Pubitemid 36050437)
192. Sairanen M, Lucas G, Ernfors P, Castren M, Castren E (2005). Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 25: 1089-1094. (Pubitemid 40268949)
193. Saito S, Watanabe K, Hashimoto E, Saito T (2009). Low serum BDNF and food intake regulation: A possible new explanation of the pathophysiology of eating disorders. Prog Neuropsychopharmacol Biol Psychiatry 33: 312-316.
194. Sales AJ, Biojone C, Terceti MS, Guimaraes FS, Gomes MV, Joca SR (2011). Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors. Br J Pharmacol. (e-pub ahead of print
195. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W (1987). Interleukin-1 stimulates the secretion of hypothalamic corticotropin- releasing factor. Science 238: 522-524. (Pubitemid 17147036)
196. Scarisbrick IA, Jones EG, Isackson PJ (1993). Coexpression of mRNAs for NGF, BDNF, and NT-3 in the cardiovascular system of the pre- and postnatal rat. J Neurosci 13: 875-893. (Pubitemid 23067578)
197. Schinder AF, Poo M (2000). The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci 23: 639-645. (Pubitemid 32007891)
198. Schmidt HD, Banasr M, Duman RS (2008). Future antidepressant targets: Neurotrophic factors and related signaling cascades. Drug Discov Today Ther Strateg 5: 151-156.
199. Schmidt HD, Duman RS (2007). The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 18: 391-418. (Pubitemid 47356367)
200. Schmidt HD, Duman RS (2010). Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 35: 2378-2391.
201. Schulte-Herbruggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A (2005). Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol 160: 204-209. (Pubitemid 40248610)
202. Sen S, Duman R, Sanacora G (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry 64: 527-532.
203. Shelton RC, Miller AH (2010). Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression. Prog Neurobiol 91: 275-299.
204. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C et al (2003). Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54: 70-75. (Pubitemid 36776725)
205. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22: 3251-3261. (Pubitemid 35379212)
206. Simen BB, Duman CH, Simen AA, Duman RS (2006). TNFalpha signaling in depression and anxiety: Behavioral consequences of individual receptor targeting. Biol Psychiatry 59: 775-785.
207. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM (1997). Antidepressant- like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 56: 131-137. (Pubitemid 27016116)
208. Skilton MR, Moulin P, Terra JL, Bonnet F (2007). Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry 62: 1251-1257. (Pubitemid 350060887)
209. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M et al (1996). Indicators of immune activation in major depression. Psychiatry Res 64: 161-167. (Pubitemid 26380235)
210. Smith MA, Makino S, Altemus M, Michelson D, Hong SK, Kvetnansky R et al (1995a). Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus coeruleus. Proc Natl Acad Sci USA 92: 8788-8792.
211. Smith MA, Makino S, Kvetnansky R, Post RM (1995b). Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 15(3 Pt 1): 1768-1777.
212. Song C, Halbreich U, Han C, Leonard BE, Luo H (2009). Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: The effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 42: 182-188.
213. Steptoe A, Hamer M, Chida Y (2007). The effects of acute psychological stress on circulating inflammatory factors in humans: A review and meta-analysis. Brain Behav Immun 21: 901-912. (Pubitemid 47285684)
214. Stewart CE, Rotwein P (1996). Growth, differentiation, and survival: Multiple physiological functions for insulin-like growth factors. Physiol Rev 76: 1005-1026. (Pubitemid 26346814)
215. Storkebaum E, Lambrechts D, Carmeliet P (2004). VEGF: Once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26: 943-954. (Pubitemid 39273068)
216. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O et al (2007). Pro- and anti-inflammatory cytokine balance in major depression: Effect of sertraline therapy. Clin Dev Immunol 2007: 76396.
217. Takebayashi M, Hisaoka K, Nishida A, Tsuchioka M, Miyoshi I, Kozuru T et al (2006). Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int J Neuropsychopharmacol 9: 607-612. (Pubitemid 44607213)
218. Taler M, Gil-Ad I, Lomnitski L, Korov I, Baharav E, Bar M et al (2007). Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol 17: 774-780. (Pubitemid 47588862)
219. Taliaz D, Loya A, Gersner R, Haramati S, Chen A, Zangen A (2011). Resilience to chronic stress is mediated by hippocampal brainderived neurotrophic factor. J Neurosci 31: 4475-4483.
220. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O'Brien JT (2005). Increase in interleukin-1beta in late-life depression. Am J Psychiatry 162: 175-177.
221. Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma M et al (1993). Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron 10: 475-489. (Pubitemid 23111738)
222. Timonen M, Laakso M, Jokelainen J, Rajala U, Meyer-Rochow VB, Keinanen-Kiukaanniemi S (2005). Insulin resistance and depression: Cross sectional study. BMJ 330: 17-18. (Pubitemid 40070469)
223. Timonen M, Rajala U, Jokelainen J, Keinanen-Kiukaanniemi S, Meyer-Rochow VB, Rasanen P (2006). Depressive symptoms and insulin resistance in young adult males: Results from the Northern Finland 1966 birth cohort. Mol Psychiatry 11: 929-933. (Pubitemid 44470215)
224. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T et al (2002). Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 110: 249-257. (Pubitemid 34804533)
225. Trejo JL, Carro E, Torres-Aleman I (2001). Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci 21: 1628-1634. (Pubitemid 32182203)
226. Trejo JL, Llorens-Martin MV, Torres-Aleman I (2008). The effects of exercise on spatial learning and anxiety-like behavior are mediated by an IGF-I-dependent mechanism related to hippocampal neurogenesis. Mol Cell Neurosci 37: 402-411.
227. Trejo JL, Piriz J, Llorens-Martin MV, Fernandez AM, Bolos M, LeRoith D et al (2007). Central actions of liver-derived insulinlike growth factor I underlying its pro-cognitive effects. Mol Psychiatry 12: 1118-1128. (Pubitemid 350191366)
228. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9: 519-525.
229. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E (2003). Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 170: 429-433. (Pubitemid 38010515)
230. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al (2006). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 367: 29-35. (Pubitemid 43038667)
231. Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B et al (2010). Pretreatment assessment of hepatocellular carcinoma: Expert consensus statement. HPB (Oxford) 12: 289-299.
232. Ventriglia M, Zanardini R, Pedrini L, Placentino A, Nielsen MG, Gennarelli M et al (2009). VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 33: 146-149.
233. von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA (2003). Interleukins in atherosclerosis: Molecular pathways and therapeutic potential. Pharmacol Rev 55: 133-166. (Pubitemid 36268401)
234. Wager TD, Davidson ML, Hughes BL, Lindquist MA, Ochsner KN (2008). Prefrontal-subcortical pathways mediating successful emotion regulation. Neuron 59: 1037-1050.
235. Wallace DL, Han MH, Graham DL, Green TA, Vialou V, Iniguez SD et al (2009). CREB regulation of nucleus accumbens excitability mediates social isolation-induced behavioral deficits. Nat Neurosci 12: 200-209.
236. Wang PS, Simon G, Kessler RC (2003). The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 12: 22-33. (Pubitemid 36675445)
237. Warner-Schmidt JL, Duman RS (2007). VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 104: 4647-4652. (Pubitemid 47186279)
238. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR et al (2004). Epigenetic programming by maternal behavior. Nat Neurosci 7: 847-854. (Pubitemid 38989508)
239. Werther GA, Abate M, Hogg A, Cheesman H, Oldfield B, Hards D et al (1990). Localization of insulin-like growth factor-I mRNA in rat brain by in situ hybridizationFrelationship to IGF-I receptors. Mol Endocrinol 4: 773-778.
240. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P et al (2000). Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA 97: 325-330. (Pubitemid 30055830)
241. Yamada N, Katsuura G, Ochi Y, Ebihara K, Kusakabe T, Hosoda K et al (2011). Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology 152: 2634-2643.
242. Yamamoto M, Sobue G, Yamamoto K, Terao S, Mitsuma T (1996). Expression of mRNAs for neurotrophic factors (NGF, BDNF, NT-3, and GDNF) and their receptors (p75NGFR, trkA, trkB, and trkC) in the adult human peripheral nervous system and nonneural tissues. Neurochem Res 21: 929-938.
243. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R et al (2000). Illness, cytokines, and depression. Ann NY Acad Sci 917: 478-487.
244. Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W et al (2007). Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31: 1034-1037. (Pubitemid 46824019)
245. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F et al (2010). Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28: 2159-2166.
246. Zanardini R, Gazzoli A, Ventriglia M, Perez J, Bignotti S, Rossini PM et al (2006). Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord 91: 83-86. (Pubitemid 43254643)
247. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM et al (2011). A framework for evaluating biomarkers for early detection: Validation of biomarker panels for ovarian cancer. Cancer Prevent Res 4: 375-383.